{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Resistant+Solid+Malignancies&page=6", "query": { "condition": "Resistant Solid Malignancies", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 189, "total_pages": 19, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Resistant+Solid+Malignancies&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Resistant+Solid+Malignancies&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T11:26:27.032Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04840589", "title": "Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Malignant Solid Neoplasm", "Recurrent Malignant Solid Neoplasm", "Recurrent Platinum-Resistant Ovarian Carcinoma", "Refractory Ovarian Carcinoma" ], "interventions": [ { "name": "BET Bromodomain Inhibitor ZEN-3694", "type": "DRUG" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2022-02-02", "completion_date": "2028-09-01", "has_results": false, "last_update_posted_date": "2026-11-12", "last_synced_at": "2026-11-15T11:26:27.032Z", "location_count": 9, "location_summary": "Bethesda, Maryland • New York, New York • The Bronx, New York + 3 more", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04840589" }, { "nct_id": "NCT04927663", "title": "11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Castration-Resistant Prostate Carcinoma", "Metastatic Prostate Carcinoma", "Stage IV Prostate Cancer AJCC v8", "Stage IVA Prostate Cancer AJCC v8", "Stage IVB Prostate Cancer AJCC v8", "Solid Tumor, Adult", "Solid Tumor", "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "11C-YJH08", "type": "DRUG" }, { "name": "Optional Tumor Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Rahul Aggarwal", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 2, "start_date": "2021-08-10", "completion_date": "2025-02-28", "has_results": true, "last_update_posted_date": "2025-05-20", "last_synced_at": "2026-11-15T11:26:27.032Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04927663" }, { "nct_id": "NCT06161025", "title": "A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Solid Cancer" ], "interventions": [ { "name": "R-DXd", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" }, { "name": "PLD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 860, "start_date": "2024-02-27", "completion_date": "2030-04-30", "has_results": false, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-11-15T11:26:27.032Z", "location_count": 45, "location_summary": "Anchorage, Alaska • New Haven, Connecticut • Coral Gables, Florida + 33 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Deerfield Beach", "state": "Florida" }, { "city": "Lake Mary", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06161025" }, { "nct_id": "NCT06799065", "title": "First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "Breast Cancer Recurrent", "Ovarian Cancer", "High-grade Serous Ovarian Carcinoma", "Triple Negative Breast Cancer", "sqNSCLC", "Squamous Non-small-cell Lung Cancer" ], "interventions": [ { "name": "ATX-295", "type": "DRUG" }, { "name": "ATX-295 and bevacizumab (or biosimilar)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Accent Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 218, "start_date": "2025-03-21", "completion_date": "2027-08-30", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-11-15T11:26:27.032Z", "location_count": 11, "location_summary": "Aurora, Colorado • Sarasota, Florida • Detroit, Michigan + 8 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06799065" }, { "nct_id": "NCT04541225", "title": "Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioma", "Glioma, Malignant", "Glioma, Mixed", "Glial Cell Tumors", "Breast Cancer", "Breast Carcinoma", "Cancer of Breast", "Cancer of the Breast", "Breast Tumor", "Malignant Tumor of Breast", "Advanced Breast Cancer", "Advanced Breast Carcinoma", "Metastatic Breast Cancer", "Metastatic Breast Carcinoma", "Prostate Cancer", "Prostatic Cancer", "Cancer of Prostate", "Cancer of the Prostate", "Prostate Neoplasm", "Castrate Resistant Prostate Cancer", "Castration-resistant Prostate Cancer", "Castration Resistant Prostatic Neoplasms", "Glioblastoma", "Recurrent Glioblastoma" ], "interventions": [ { "name": "NUV-422", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nuvation Bio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2020-12-08", "completion_date": "2022-08-31", "has_results": false, "last_update_posted_date": "2023-07-14", "last_synced_at": "2026-11-15T11:26:27.032Z", "location_count": 12, "location_summary": "Tucson, Arizona • Miami, Florida • Boston, Massachusetts + 9 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Huntersville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04541225" }, { "nct_id": "NCT02020707", "title": "Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cervical Adenocarcinoma", "Cervical Adenosarcoma", "Cervical Adenosquamous Carcinoma", "Cervical Carcinosarcoma", "Cervical Squamous Cell Carcinoma", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Endometrial Adenosquamous Carcinoma", "Endometrial Clear Cell Adenocarcinoma", "Endometrial Endometrioid Adenocarcinoma", "Endometrial Mixed Cell Adenocarcinoma", "Endometrial Mucinous Adenocarcinoma", "Endometrial Serous Adenocarcinoma", "Endometrial Undifferentiated Carcinoma", "Fallopian Tube Adenocarcinoma", "Fallopian Tube Carcinosarcoma", "Fallopian Tube Clear Cell Adenocarcinoma", "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube Mucinous Adenocarcinoma", "Fallopian Tube Serous Adenocarcinoma", "Fallopian Tube Squamous Cell Carcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Fallopian Tube Undifferentiated Carcinoma", "Malignant Female Reproductive System Neoplasm", "Malignant Ovarian Clear Cell Tumor", "Malignant Ovarian Endometrioid Tumor", "Malignant Ovarian Epithelial Tumor", "Malignant Ovarian Mucinous Tumor", "Malignant Peritoneal Neoplasm", "Malignant Solid Neoplasm", "Ovarian Carcinosarcoma", "Ovarian Clear Cell Adenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian High Grade Serous Adenocarcinoma", "Ovarian Mucinous Adenocarcinoma", "Ovarian Serous Adenocarcinoma", "Ovarian Transitional Cell Carcinoma", "Ovarian Undifferentiated Carcinoma", "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Ovarian Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Platinum-Sensitive Ovarian Carcinoma", "Primary Peritoneal Carcinosarcoma", "Primary Peritoneal Clear Cell Adenocarcinoma", "Primary Peritoneal Serous Adenocarcinoma", "Primary Peritoneal Transitional Cell Carcinoma", "Primary Peritoneal Undifferentiated Carcinoma", "Unresectable Melanoma", "Uterine Corpus Carcinosarcoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2014-02-24", "completion_date": "2024-07-18", "has_results": false, "last_update_posted_date": "2024-07-26", "last_synced_at": "2026-11-15T11:26:27.032Z", "location_count": 4, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 1 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02020707" }, { "nct_id": "NCT04514484", "title": "Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Differentiated Thyroid Gland Carcinoma", "Advanced Head and Neck Carcinoma", "Advanced Hepatocellular Carcinoma", "Advanced Kaposi Sarcoma", "Advanced Lung Non-Small Cell Carcinoma", "Advanced Lung Small Cell Carcinoma", "Advanced Malignant Solid Neoplasm", "Advanced Melanoma", "Advanced Ovarian Carcinoma", "Advanced Prostate Carcinoma", "Advanced Renal Cell Carcinoma", "Advanced Thyroid Gland Medullary Carcinoma", "Advanced Triple-Negative Breast Carcinoma", "Advanced Urothelial Carcinoma", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Castration-Resistant Prostate Carcinoma", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "HIV Infection", "Metastatic Differentiated Thyroid Gland Carcinoma", "Metastatic Head and Neck Carcinoma", "Metastatic Hepatocellular Carcinoma", "Metastatic Kaposi Sarcoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Lung Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Ovarian Carcinoma", "Metastatic Prostate Carcinoma", "Metastatic Renal Cell Carcinoma", "Metastatic Thyroid Gland Medullary Carcinoma", "Metastatic Triple-Negative Breast Carcinoma", "Metastatic Urothelial Carcinoma", "Recurrent Differentiated Thyroid Gland Carcinoma", "Recurrent Head and Neck Carcinoma", "Recurrent Hepatocellular Carcinoma", "Recurrent Kaposi Sarcoma", "Recurrent Lung Non-Small Cell Carcinoma", "Recurrent Lung Small Cell Carcinoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Melanoma", "Recurrent Ovarian Carcinoma", "Recurrent Prostate Carcinoma", "Recurrent Renal Cell Carcinoma", "Recurrent Thyroid Gland Medullary Carcinoma", "Recurrent Triple-Negative Breast Carcinoma", "Recurrent Urothelial Carcinoma", "Refractory Differentiated Thyroid Gland Carcinoma", "Stage III Differentiated Thyroid Gland Carcinoma AJCC v8", "Stage III Hepatocellular Carcinoma AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Ovarian Cancer AJCC v8", "Stage III Prostate Cancer AJCC v8", "Stage III Renal Cell Cancer AJCC v8", "Stage III Thyroid Gland Medullary Carcinoma AJCC v8", "Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IV Prostate Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IV Thyroid Gland Medullary Carcinoma AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cabozantinib S-malate", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2021-11-22", "completion_date": "2027-02-06", "has_results": true, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-11-15T11:26:27.032Z", "location_count": 3, "location_summary": "Chicago, Illinois • The Bronx, New York • Pittsburgh, Pennsylvania", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "The Bronx", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04514484" }, { "nct_id": "NCT03811652", "title": "A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Small Cell Lung Cancer Squamous (NSCLC-Sq)", "Head and Neck Squamous Cell Carcinoma (HNSCC)", "Small Cell Lung Cancer (SCLC)", "Pancreatic Ductal Adenocarcinoma (PDAC)", "Colorectal Cancer (CRC)", "Metastatic Castration-resistant Prostate Cancer (mCRPC)" ], "interventions": [ { "name": "MEDI7247", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "101 Years", "sex": "ALL", "summary": "18 Years to 101 Years" }, "enrollment_count": 8, "start_date": "2018-12-20", "completion_date": "2019-12-10", "has_results": false, "last_update_posted_date": "2019-12-30", "last_synced_at": "2026-11-15T11:26:27.032Z", "location_count": 2, "location_summary": "Huntersville, North Carolina • Nashville, Tennessee", "locations": [ { "city": "Huntersville", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03811652" }, { "nct_id": "NCT03861403", "title": "A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "Advanced Triple Negative Breast Cancer", "Advanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer", "Advanced Metastatic Castration-Resistant Prostate Cancer", "Advanced Platinum-Resistant Ovarian Cancer" ], "interventions": [ { "name": "TRX518", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Avelumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Leap Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2019-05-20", "completion_date": "2020-07-14", "has_results": false, "last_update_posted_date": "2023-11-30", "last_synced_at": "2026-11-15T11:26:27.032Z", "location_count": 4, "location_summary": "Lafayette, Indiana • New York, New York • Cleveland, Ohio + 1 more", "locations": [ { "city": "Lafayette", "state": "Indiana" }, { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03861403" }, { "nct_id": "NCT00770263", "title": "Erlotinib and Temsirolimus for Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Erlotinib", "type": "DRUG" }, { "name": "Temsirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2009-05", "completion_date": "2014-09", "has_results": false, "last_update_posted_date": "2015-06-03", "last_synced_at": "2026-11-15T11:26:27.032Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00770263" } ] }